Clopidogrel Versus Cilostazol on Vessels

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-16

Study Completion Date

2027-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Diabetes is an increasing cause of atherosclerotic and cardiovascular illnesses in South Korea. The clinical application of ultrasound for measuring carotid intima-media thickness, which helps in early detection and surveillance of atherosclerosis, is advancing. Due to lifestyle changes and an aging population, Koreans, especially diabetics, are developing more vascular diseases and are at higher risk for peripheral vascular disorders. Diabetics with lower limb peripheral artery disease require effective therapy to avoid major complications and a reduced quality of life. Although licensed for symptom control, Clopidogrel and Cilostazol have not yet been established for primary prevention of cardiovascular risks. These medications will be evaluated for their potential as primary preventive agents against cardiovascular disease in type 2 diabetes patients. The goal of this research is to investigate the efficacy of Cilostazol and Clopidogrel in inhibiting the progression of carotid atherosclerosis and to evaluate their influence on hemorheological changes in individuals with Type 2 diabetes. The goal of this research is to investigate the efficacy of Cilostazol and Clopidogrel in inhibiting the progression of carotid atherosclerosis and evaluating their influence on alterations in blood flow among individuals with Type 2 diabetes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Comparison of Effects Between Increased Dose of Clopidogrel and Addition of Cilostazol

NCT00620646

Clopidogrel Non-Responsiveness

COMPLETED NA

Clopidogrel Resistance and Embolism in Carotid Artery Stenting

NCT02133989

Carotid Stenosis

UNKNOWN PHASE3

Investigation of the Athero-Protective Effects of Clopidogrel

NCT01283282

Coronary Artery Disease

COMPLETED PHASE4

Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Chronic Kidney Disease

NCT01328470

Chronic Kidney Disease Stable Angina

COMPLETED PHASE4

Clopidogrel Preventive Effect Based on CYP2C19 Genotype in Ischemic Stroke

NCT04072705

Acute Ischemic Stroke

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 2 Diabetes Atherosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Clopidogrel

Clopidogrel 75mg once daily

Group Type EXPERIMENTAL

Clopidogrel

Intervention Type DRUG

Clopidogrel 75mg once daily

Cilostazol

Cilostazol 200mg per day

Group Type ACTIVE_COMPARATOR

Cilostazol

Intervention Type DRUG

Cilostazol 200mg per day

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Clopidogrel

Clopidogrel 75mg once daily

Intervention Type DRUG

Cilostazol

Cilostazol 200mg per day

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Platless Tab. Cilostan CR Tab. 200mg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults with diabetes aged 19 and older
* Individuals with a carotid ultrasound cIMT (carotid intima-media thickness) of 1.0mm or more
* Those who have not changed their combination therapy medications (including oral hypoglycemics, antihypertensives, and lipid-lowering drugs) in the last three months
* Individuals with an HbA1c level of 10% or less
* Those who have voluntarily signed the written consent form and agreed to participate in the study

Exclusion Criteria

* Individuals currently using antithrombotic or anticoagulant medications other than aspirin
* Individuals with bleeding or conditions that may increase the risk of bleeding, such as:

* Hemophilia, capillary fragility, intracranial hemorrhage, upper gastrointestinal bleeding, urinary bleeding, hemoptysis, vitreous hemorrhage, etc
* Active peptic ulcer, hemorrhagic stroke within the last 6 months, surgical operations within the last 3 months, proliferative diabetic retinopathy, uncontrolled hypertension
* Patients who have had cerebrovascular or cardiovascular complications within the past 6 months (including stroke, transient ischemic attacks, myocardial infarction, unstable angina, coronary artery bypass graft, or percutaneous coronary intervention)
* Patients with severe renal or hepatic diseases
* Patients with congestive heart failure
* Individuals with a history of hypersensitivity to the drug or its components
* Pregnant women or women who may be pregnant
* Women who are breastfeeding or plan to breastfeed during the study

Minimum Eligible Age

19 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No